DRL
DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT
In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
Stocks in news: HDFC Bank, Infosys, Yes Bank, Hindustan Zinc and RVNL
Indian equities continued their downward trend due to rising global bond yields and high crude oil prices. The Nifty 50 fell by 198.50 points, while the BSE Sensex decreased by 570.59 points. Key companies like HDFC Bank and Infosys made significant corporate announcements amidst these market conditions. HDFC Bank appointed a new Managing Director and CEO following regulatory approval.
2026 Mahindra Thar OG launched at Rs 10.32 lakh: What’s new in the 3-door SUV, features, pics, variants and delivery date
Mahindra Thar OG Launched: Mahindra has launched the Thar OG at an introductory price of Rs 10.32 lakh (ex-showroom), with deliveries set to begin from October 11, 2026. The new three-door SUV gets the M_Glyde 4G platform, revised suspension with DAVINCI Damping, more powerful petrol and diesel engines, an Electronic Locking Differential, terrain modes, updated styling and six airbags.
Takeda partners Dr Reddy's to launch dengue vaccine Qdenga in India from 2027
Takeda and Dr. Reddy's Labs will promote the Qdenga dengue vaccine in India. This pioneering vaccine is expected to launch in the first half of 2027. It will be available for paediatric and adult vaccination in the private market. The vaccine received approval from India's regulatory agency in July 2026. Pricing details for the Indian market have not yet been disclosed.
QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it
India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.
Trump plans $4 million for right-wing media in Europe, sources say
The Trump administration plans to allocate at least $25 million to European civil society groups, including $4 million aimed at strengthening right-wing media and journalism. The funding, described by the State Department as supporting free speech and transatlantic ties, has triggered concerns in Europe over potential US interference in domestic politics.
- Go To Page 1
DRL, Emcure get approval to make breakthrough HIV drug
India's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for local clinical trials. This move will improve access to the HIV prevention injection. Lenacapavir is a breakthrough twice-yearly injection for HIV prevention. Patient groups had urged the regulator to expedite this process.
Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommend
Dr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Thursday's trade. While its revenue from operations increased by 15.28% YoY to Rs 5,843 crore, total expenses were down 4% at Rs 5,132.2 crore. US revenues fell 17% QoQ. Jefferies maintained its Buy rating on Dr Reddy’s Laboratories with a target price of Rs 5,650, while Prabhudas Lilladher downgraded the stock to Reduce with a revised target price of Rs 4,500 from Rs 4,900.
What CLSA says on Lupin; Morgan Stanley on DRL, Godrej Consumer
In the case of DRL, Morgan Stanley said that the drug maker continued to deliver granular growth and that the growth trend should continue in FY23.
DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fall
Edelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage sees Ebitda margin falling 14 basis points YoY to 22.7 per cent, with input cost headwinds partly compensated by plateauing SG&A investments.
Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimate
The drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat Street estimates.
Dr Reddy's strong product pipeline and other factors that make it stock pick of the week
DRL continues to generate free cash flows (FCFs) due to strongholds in some legacy drugs. Its lower valuation compared to its peers and strong balance sheet, are the other factors that have made the company a favourite of analysts.
US turnaround drives DRL’s stellar Q4 show
DRL’s strategy pivot, with focus on the core areas of US generics, India and emerging markets, has been yielding results.
DRL surges; company announces strategic alliance with Biocodex
Biocodex has announced a change in partnership from October 1, giving complete rights to DRL for promotion and distribution of its products across Romania.
Sell DRL Ltd with a target of Rs 2510: Sandeep Wagle
DRL Ltd is a ‘SELL’ call with a target of Rs 2510 and a stop loss of Rs 2690.
Genzyme Corporation files patent infringement suit against DRL
Mozobil (plerixafor injection) is a hematopoietic stem cell mobiliser indicated to patients with non-Hodgkin's lymphoma (blood cancer) and multiple myeloma.
Brokerages raise price target on Dr Reddy's to as high as Rs 2,720 on FDA nod
Brokerages see the FDA approval to Dr Reddy’s Laboratories (DRL) for generic Vidaza as a positive for the company.
Fresenius files patent infringements suit against DRL in US
Fresenius Kabi has dragged leading pharmaceuticals company Dr Reddy's to court for allegedly infringing on the former's patented anaesthetic Diprivan.
Bristol-Myers sues Dr Reddy's Laboratories for patent infringement in US
Bristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories over the cancer drug Ixempra.
Dr Reddy's starts Phase-II trials of DRL-17822 molecule
Phase-II clinical trials are conducted on a larger sample of human subjects (20-300) to assess how well a drug works.
Growth in US, local market to pep up DRL
Dr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen trading sessions.
GSK drug-deal talk lifts DRL scrip
Shares of Dr Reddy’s Laboratories (DRL) touched an intra-day high of Rs 878.70, amid speculation that the Indian drug maker is in preliminary talks with UK-based GlaxoSmithKline (GSK) to market Red Heart Pill, used to treat those with heart ailments.
DRL faces patent suit in US over allergy generic
NYSE-listed Dr Reddy’s Laboratories (DRL) is embroiled in a fresh patent infringement row with US-based drug-discovery firm Albany Molecular Research (AMRI).
DRL seeks USFDA help to make cancer drug clone
US-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.
Citigroup assigns 'hold' rating to Dr Reddy's Laboratories
Citigroup has assigned a ‘hold’rating to Dr Reddy’s Laboratories (DRL) with a price target of Rs 547.
Dr Reddy's looks at settling Sanofi dispute out of court
Pharma major Dr Reddy’s Laboratories (DRL) is contemplating an out-of-court settlement with the French company Sanofi-Aventis for anti-allergy drug Allegra.
Dr Reddy's Laboratories wins round 1 of patent war
US court dismisses one of the three patent claims made by Roche for Boniva; DRL still in litigation for two other listed patents.
DRL, Novartis smoke peace pipe on Alzheimer's drug
Dr Reddy’s Laboratories (DRL) has entered a settlement agreement with Novartis Pharma to suspend the launch of its generic capsule rivastigmine tartrate till 2014.
DRL bets on India plan for German arm
Dr Reddy’s Laboratories (DRL) aims to shift production of about a dozen top-selling products of its German arm Betapharm to India by July 2008 as it battles a supply crunch and price pressures in the European nation.
Load More
